文献速递心力衰竭与心肌病

达格列净在不同地域心衰患者中的疗效一致

Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2023-08-21

本研究汇总DAPA-HF与DELIVER试验共11,007例患者,按地域分析达格列净疗效。北美主要结局事件率较高(13.9/100人年),但达格列净对主要结局的获益无地域差异(P交互=0.40),在HFrEF和HFmrEF/HFpEF中结果一致。

要点

  • 达格列净降低心衰恶化或心血管死亡风险不受地域影响。
  • 北美事件率较高但治疗获益与其他地区一致。
  • HFrEF与HFmrEF/HFpEF亚组中地域交互作用均不显著。

核心结论

  • 达格列净的疗效和安全性在全球各区域间一致,尽管患者特征、背景治疗和事件率存在地域差异。

研究设计与样本

  • 患者水平汇总分析,纳入DAPA-HF和DELIVER两项试验,共11,007例心衰患者。

主要发现

  • 主要结局事件率(每100人年)北美为13.9(95%CI 12.5-15.4),欧洲10.8(95%CI 10.1-11.5),南美10.0(95%CI 9.0-11.1),亚洲10.5(95%CI 9.5-11.5)。
  • 达格列净 vs 安慰剂对主要结局的HR:欧洲0.85(95%CI 0.75-0.96),北美0.75(95%CI 0.61-0.93),南美0.72(95%CI 0.58-0.89),亚洲0.74(95%CI 0.61-0.91),P交互=0.40。
  • HFrEF亚组P交互=0.39,HFmrEF/HFpEF亚组P交互=0.84。
  • 北美停药率高于其他地区(安慰剂停药:北美21.8% vs 南美6.4%),但各区域内安慰剂与达格列净停药率无差异。

临床怎么用

  • 达格列净可用于不同地域的心衰患者,疗效不受地域影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Because clinical characteristics and prognosis vary by geographic region in patients with heart failure (HF), the response to treatment may also vary. A previous report suggested that the efficacy of sodium-glucose cotransporter-2 inhibitor efficacy in heart failure with reduced ejection fraction (HFrEF) may be modified by region. OBJECTIVES: The goal of this study was to examine the efficacy and safety of dapagliflozin in patients with HF according to geographic region. METHODS: We conducted a patient-level pooled analysis of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trials, which evaluated the effects of dapagliflozin in HFrEF and heart failure with mildly reduced ejection fraction (HFmrEF)/heart failure with preserved ejection fraction (HFpEF), respectively. The primary outcome was the composite of worsening HF or cardiovascular death. RESULTS: Among 11,007 patients, 5,159 (46.9%) were enrolled in Europe, 1,528 (13.9%) in North America, 1,998 (18.2%) in South America, and 2,322 (21.1%) in Asia. The rate of the primary outcome (per 100 person-years) was higher in North America (13.9 [95% CI: 12.5-15.4]) than in other regions: Europe 10.8 (95% CI: 10.1-11.5), South America 10.0 (95% CI: 9.0-11.1), and Asia 10.5 (95% CI: 9.5-11.5). The benefit of dapagliflozin on the primary outcome was not modified by region: dapagliflozin vs placebo HR: Europe, 0.85 (95% CI: 0.75-0.96); North America, 0.75 (95% CI: 0.61-0.93); South America, 0.72 (95% CI: 0.58-0.89); and Asia, 0.74 (95% CI: 0.61-0.91) (P interaction = 0.40). This was the same when evaluated separately for HFrEF (P interaction = 0.39) and HFmrEF/HFpEF (P interaction = 0.84). Patients in North America discontinued randomized treatment more frequently than did those elsewhere (placebo discontinuation: 21.8% in North America vs 6.4% in South America), but discontinuation rates did not differ between placebo and dapagliflozin by region. CONCLUSIONS: The efficacy and safety of dapagliflozin were consistent across global regions despite geographic differences in patient characteristics, background treatment, and event rates.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kondo, Wang, Yang, et al. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. J Am Coll Cardiol. 2023. PMID: 37610398. doi:10.1016/j.jacc.2023.05.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。